A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

‘Can We Cure Cancer with Artificial Intelligence?’ Predictive Oncology Announces DojoLIVE! Interview with Helomics CIO Mark Collins

What To Know

  • Helomics is leveraging this unique TDRP platform and huge knowledge base to pioneer the development of AI-driven models of tumor drug response and outcome that, in partnership with pharmaceutical companies, will enable lower cost, faster and smarter discovery of new therapies.
  • The company uses its unique clinically validated Tumor Drug Response Profiling (TDRP) platform to generate a comprehensive profile of the patient tumor to guide the oncologist in individualizing treatment.

Predictive Oncology Inc. (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announces that Mark Collins, Ph.D., chief innovation officer of its Helomics subsidiary, recently appeared on DojoLIVE!, a lively podcast and interview forum that brings together a broad roster of technology, business and thought leaders from a wide range of software companies and startups.

The broadcast, titled ‘Can We Cure Cancer With Artificial Intelligence?’, is available for on-demand viewing on the DojoLIVE! website.

As noted during the interview, Collins possesses a passion for applying science to build high-tech life-science products and services that impact the search for new medicines. He feels that Helomics, a division of Predictive Oncology, is uniquely positioned to deliver on this goal.

Helomics aims to improve outcomes for the cancer patients of today and in the future by harnessing the power of the patient’s own living tumor. The company uses its unique clinically validated Tumor Drug Response Profiling (TDRP) platform to generate a comprehensive profile of the patient tumor to guide the oncologist in individualizing treatment. In use for 15+ years, this platform has generated drug response and genomic profiles on over 150,000 tumors – the largest knowledge base of its kind in the world.

Helomics is leveraging this unique TDRP platform and huge knowledge base to pioneer the development of AI-driven models of tumor drug response and outcome that, in partnership with pharmaceutical companies, will enable lower cost, faster and smarter discovery of new therapies. Furthermore, once validated, these AI-models will be used as clinical decision support tools to help clinicians individualize cancer treatment with current therapies.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Under a license agreement, Biopredic will leverage Preci’s expertise and production capacity in sourcing primary hepatocytes, and combine with its own IP and know-how in cell pooling. The partnership will provide DMPK researchers access to large batches of high-performing suspended pooled hepatocytes with extended longevity from multiple donors.
The future of biotechnology holds immense promise, with continued advancements driving innovation and progress across various sectors. From gene editing and synthetic biology to biopharmaceuticals and beyond, the possibilities are endless. By staying informed, collaborating with industry leaders, and leveraging cutting-edge technologies, we can harness the power of biotechnology to address some of the most pressing challenges facing humanity.
"In a medical first, we have now dosed our first patient in a clinical trial using their own lymph nodes as living bioreactors to regenerate an ectopic organ," said Dr. Michael Hufford, Co-Founder and CEO of LyGenesis. "This therapy will potentially be a remarkable regenerative medicine milestone by helping patients with ESLD grow new functional ectopic livers in their own body. If our study is successful and we obtain FDA approval, our allogenic cell therapy could enable one donated liver to treat many dozens of ESLD patients, which could help to tilt the current organ supply-demand imbalance in favor of patients."
The relationship between pharmaceutical companies and CDMOs is fundamentally collaborative, fostering an environment of innovation. By partnering with a CDMO, pharmaceutical firms can access a wide array of technologies and expertise that might otherwise be beyond their reach.
Serum Detect is developing diagnostic tests, using standard liquid biopsy samples, that complement and enhance existing screening techniques for early detection of cancer.

By using this website you agree to accept Medical Device News Magazine Privacy Policy